nifedipine has been researched along with Hyperaldosteronism in 16 studies
Nifedipine: A potent vasodilator agent with calcium antagonistic action. It is a useful anti-anginal agent that also lowers blood pressure.
Hyperaldosteronism: A condition caused by the overproduction of ALDOSTERONE. It is characterized by sodium retention and potassium excretion with resultant HYPERTENSION and HYPOKALEMIA.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Therefore, we have studied the acute and chronic effect of nifedipine in 7 patients with idiopathic hyperaldosteronism (IHA) and 8 with aldosterone producing adenoma (APA)." | 9.06 | Acute and chronic effect of nifedipine in primary aldosteronism. ( Carpenè, G; Mantero, F; Opocher, G; Rocco, S, 1989) |
| "To measure the plasma concentrations of adrenomedullin (ADM),atrial natriuretic peptide (ANP), and brain natriuretic peptide (BNP), and investigate their pathophysiological functions in patients with primary aldosteronism (PA)." | 7.81 | Pathophysiological functions of adrenomedullin and natriuretic peptides in patients with primary aldosteronism. ( Hu, W; Wang, W; Xu, CG; Zhang, XB; Zhou, PH, 2015) |
| " Study 1: A long-term (4 weeks) treatment with slow-release nifedipine (Nif), 40-60 mg/day, was performed in 9 in-patients with essential hypertension (EHT)." | 7.69 | [Mechanism of inhibition of aldosterone secretion by a Ca2+ channel blocker in patients with essential hypertension and patients with primary aldosteronism]. ( Iimura, O; Shimamoto, K; Yokoyama, T, 1995) |
| " Therefore, we have studied the acute and chronic effect of nifedipine in 7 patients with idiopathic hyperaldosteronism (IHA) and 8 with aldosterone producing adenoma (APA)." | 5.06 | Acute and chronic effect of nifedipine in primary aldosteronism. ( Carpenè, G; Mantero, F; Opocher, G; Rocco, S, 1989) |
| "To measure the plasma concentrations of adrenomedullin (ADM),atrial natriuretic peptide (ANP), and brain natriuretic peptide (BNP), and investigate their pathophysiological functions in patients with primary aldosteronism (PA)." | 3.81 | Pathophysiological functions of adrenomedullin and natriuretic peptides in patients with primary aldosteronism. ( Hu, W; Wang, W; Xu, CG; Zhang, XB; Zhou, PH, 2015) |
| "A 66-year-old hypertensive diabetic patient with latent hypoaldosteronism and mild renal failure was treated by adding enalapril, an angiotensin converting enzyme inhibitor, to the furosemide and nifedipine regimen because of an insufficient antihypertensive response for 1 month." | 3.69 | Reversible hyperkalemia during antihypertensive therapy in a hypertensive diabetic patient with latent hypoaldosteronism and mild renal failure. ( Azukizawa, S; Kaneko, M; Kigoshi, T; Matsui, A; Morimoto, S; Nakano, S; Uchida, K, 1994) |
| " Study 1: A long-term (4 weeks) treatment with slow-release nifedipine (Nif), 40-60 mg/day, was performed in 9 in-patients with essential hypertension (EHT)." | 3.69 | [Mechanism of inhibition of aldosterone secretion by a Ca2+ channel blocker in patients with essential hypertension and patients with primary aldosteronism]. ( Iimura, O; Shimamoto, K; Yokoyama, T, 1995) |
| "To determine the potential therapeutic effect of calcium entry blockade in primary aldosteronism, 10 patients (5 adenoma and 5 hyperplasia) documented by endocrine testing and/or surgery were given nifedipine (20 mg, sublingually) in the afternoon." | 3.67 | Therapeutic effect of calcium channel blockade in primary aldosteronism. ( Horton, R; Hsueh, W; Nadler, JL, 1985) |
| "A case or primary hyperaldosteronism due to unilateral macronodular adrenal hyperplasia is presented." | 2.38 | [Primary hyperaldosteronism caused by unilateral macronodular hyperplasia]. ( Bernardin, M; Chapuis, Y; Dorey, F; Fouchard, J; Louvel, A; Luton, JP, 1989) |
| " Nifedipine and irbesartan were taken after discharge, and the dosage was reduced gradually under supervision." | 1.48 | Hypertensive crisis with 2 target organ impairment induced by glycyrrhizin: A case report. ( Fan, X; Li, J; Wang, Q, 2018) |
| "Primary hyperaldosteronism was detected in 1% of patients evaluated for secondary hypertension in a referral hospital in Southern India." | 1.29 | Primary hyperaldosteronism--diagnostic approach and management. ( Cherian, AM; Jesudason, SR; Kanagasabapathy, AS; Nair, A; Seshadri, MS, 1993) |
| "Primary hyperaldosteronism is an uncommon disorder, and there are few reports of its occurrence and management in pregnancy." | 1.29 | Primary hyperaldosteronism in pregnancy. A case report. ( Moore, F; Seely, EW; Solomon, CG; Thiet, M, 1996) |
| "Treatment with spironolactone alone, or in combination with either intravenous dopamine or ibopamine orally, amiloride, enalapril, hydralazine or clonidine corrected serum potassium values but failed to normalize blood pressure and to correct plasma renin activity and plasma aldosterone." | 1.28 | A neonate with idiopathic hyperaldosteronism. ( Derkx, FH; Donckerwolcke, RA; Griffiven, AW; Schalekamp, MA; Vande Walle, JG; Veenhoven, RH; Wit, JM, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (37.50) | 18.7374 |
| 1990's | 7 (43.75) | 18.2507 |
| 2000's | 1 (6.25) | 29.6817 |
| 2010's | 2 (12.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Li, J | 1 |
| Fan, X | 1 |
| Wang, Q | 1 |
| Hu, W | 1 |
| Zhou, PH | 1 |
| Zhang, XB | 1 |
| Xu, CG | 1 |
| Wang, W | 1 |
| Gouet, D | 1 |
| Rouffineau, J | 1 |
| Marechaud, R | 1 |
| Thomas, P | 1 |
| Pourrat, O | 1 |
| Alcalay, M | 1 |
| Bontoux, D | 1 |
| Bartorelli, A | 1 |
| Fiorentini, C | 1 |
| Fabbiocchi, F | 1 |
| Loaldi, A | 1 |
| Guazzi, M | 1 |
| Uchida, K | 1 |
| Azukizawa, S | 1 |
| Nakano, S | 1 |
| Kaneko, M | 1 |
| Kigoshi, T | 1 |
| Morimoto, S | 1 |
| Matsui, A | 1 |
| Seshadri, MS | 1 |
| Kanagasabapathy, AS | 1 |
| Cherian, AM | 1 |
| Nair, A | 1 |
| Jesudason, SR | 1 |
| Yokoyama, T | 1 |
| Shimamoto, K | 1 |
| Iimura, O | 1 |
| Solomon, CG | 1 |
| Thiet, M | 1 |
| Moore, F | 1 |
| Seely, EW | 1 |
| Al Saad, KO | 1 |
| Chan, NH | 1 |
| Bueno Errandonea, A | 1 |
| Estopiñán García, V | 1 |
| Mariscal Bernal, JA | 1 |
| Muñoz Pérez, MA | 1 |
| Kaesemeyer, WH | 1 |
| Prisant, LM | 1 |
| Carr, AA | 1 |
| Veenhoven, RH | 1 |
| Vande Walle, JG | 1 |
| Donckerwolcke, RA | 1 |
| Wit, JM | 1 |
| Griffiven, AW | 1 |
| Derkx, FH | 1 |
| Schalekamp, MA | 1 |
| Bernardin, M | 1 |
| Dorey, F | 1 |
| Louvel, A | 1 |
| Fouchard, J | 1 |
| Chapuis, Y | 1 |
| Luton, JP | 1 |
| Carpenè, G | 1 |
| Rocco, S | 1 |
| Opocher, G | 1 |
| Mantero, F | 1 |
| Kramer, HJ | 1 |
| Glänzer, K | 1 |
| Sorger, M | 1 |
| Nadler, JL | 1 |
| Hsueh, W | 1 |
| Horton, R | 1 |
1 review available for nifedipine and Hyperaldosteronism
| Article | Year |
|---|---|
[Primary hyperaldosteronism caused by unilateral macronodular hyperplasia].
Topics: Adrenal Gland Diseases; Adrenal Glands; Adult; Clonidine; Follow-Up Studies; Humans; Hyperaldosteron | 1989 |
1 trial available for nifedipine and Hyperaldosteronism
| Article | Year |
|---|---|
Acute and chronic effect of nifedipine in primary aldosteronism.
Topics: Adenoma; Aldosterone; Antihypertensive Agents; Blood Pressure; Humans; Hyperaldosteronism; Nifedipin | 1989 |
14 other studies available for nifedipine and Hyperaldosteronism
| Article | Year |
|---|---|
Hypertensive crisis with 2 target organ impairment induced by glycyrrhizin: A case report.
Topics: Anti-Inflammatory Agents; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Cholangitis; | 2018 |
Pathophysiological functions of adrenomedullin and natriuretic peptides in patients with primary aldosteronism.
Topics: Adrenalectomy; Adrenomedullin; Adult; Atrial Natriuretic Factor; Essential Hypertension; Female; Hum | 2015 |
[Arterial hypertension with secondary hyperaldosteronism, reversible by nifedipine, in systemic scleroderma].
Topics: Aged; Female; Humans; Hyperaldosteronism; Hypertension; Nifedipine; Scleroderma, Systemic | 1983 |
[Nifedipine in the therapy of secondary hypertension].
Topics: Adrenal Gland Neoplasms; Humans; Hyperaldosteronism; Hypertension; Hypertension, Renovascular; Nifed | 1981 |
Reversible hyperkalemia during antihypertensive therapy in a hypertensive diabetic patient with latent hypoaldosteronism and mild renal failure.
Topics: Aged; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Drug Therapy, Combination; Enalapril; Furos | 1994 |
Primary hyperaldosteronism--diagnostic approach and management.
Topics: Adult; Female; Follow-Up Studies; Humans; Hyperaldosteronism; Hypokalemia; Male; Middle Aged; Nifedi | 1993 |
[Mechanism of inhibition of aldosterone secretion by a Ca2+ channel blocker in patients with essential hypertension and patients with primary aldosteronism].
Topics: Adult; Aged; Aldosterone; Calcium Channel Blockers; Depression, Chemical; Female; Humans; Hyperaldos | 1995 |
Primary hyperaldosteronism in pregnancy. A case report.
Topics: Adrenal Glands; Adrenalectomy; Adult; Aldosterone; Antihypertensive Agents; Blood Pressure; Combined | 1996 |
Test and teach. Surgically correctable hypertension. Conn's syndrome and spironolactone bodies.
Topics: Adenoma; Adrenal Cortex Neoplasms; Adrenalectomy; Aldosterone; Humans; Hyperaldosteronism; Hypertens | 2001 |
[Nifedipine in the treatment of primary hyperaldosteronism].
Topics: Humans; Hyperaldosteronism; Male; Middle Aged; Nifedipine | 1992 |
Verapamil and nifedipine in combination for the treatment of hypertrophy heart disease.
Topics: Adrenal Gland Diseases; Blood Pressure; Cardiovascular Diseases; Drug Therapy, Combination; Humans; | 1991 |
A neonate with idiopathic hyperaldosteronism.
Topics: Aldosterone; Calcium; Gastrointestinal Diseases; Humans; Hyperaldosteronism; Hypokalemia; Infant, Ne | 1991 |
The role of endogenous inhibition of Na-K-ATPase in human hypertension--sodium pump activity as a determinant of peripheral vascular resistance.
Topics: Animals; ATPase Inhibitory Protein; Calcium Channel Blockers; Heart; Hemodynamics; Humans; Hyperaldo | 1985 |
Therapeutic effect of calcium channel blockade in primary aldosteronism.
Topics: Adenoma; Adrenal Cortex Neoplasms; Adult; Aged; Aldosterone; Blood Pressure; Female; Humans; Hyperal | 1985 |